Aim: To assess the diagnostic accuracies of APRI and FIB4 in predicting various stages of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) and to determine their correlation with Fibroscan.Material and methods: The patients were identified using ultrasound imaging and both males and females were included in the study. This research covered all individuals who were diagnosed with non-alcoholic fatty liver disease (NAFLD). The laboratory test findings that were assessed included those within the hospital records. The collected findings were all acquired during a one-month timeframe after a Fibroscan test. The standard range for serum alanine aminotransferase (ALT) in a laboratory is 30 - 65 U/L. The established upper limits for serum ALT levels were 45.25 U/L for men and 30.47 U/L for females. The usual reference range for serum aspartate aminotransferase (AST) is 15-37 U/L, whereas the normal reference range for platelet counts is 150-400 k/uL. Results:The average APRI and FIB-4 values for the participants in the research were 0.88±0.12 and 1.66±0.34, respectively. Non-alcoholic fatty liver disease (NAFLD) fibrosis was seen in 43.75% of the participants. Specifically, fibrosis stages G1, G2, G3, and G4 were found in 21.25%, 8.75%, 10%, and 3.75% of the participants, respectively. According to the FibroScan findings, 50% of the cases were categorized as F1, 31.25% as F2, 12.5% as F3, and 6.25% as F4. The mean values of AST/ALT, APRI, and FIB-4 were higher in the F3+F4 grade compared to the F1+F2 grade. When comparing mean AST/ALT, APRI, and FIB-4 based on fibroscan findings, a significant difference was seen in relation to APRI and FIB-4, with a p-value of less than 0.05. AST/ALT has the lowest sensitivity and specificity when it comes to predicting various stages of liver fibrosis in individuals with non-alcoholic fatty liver disease (NAFLD).Conclusion: Our findings indicate that APRI is the most effective marker for predicting advanced liver fibrosis when compared to the AST/ALT ratio. Additionally, APRI shows a similar level of accuracy as FIB-4, but exhibits the highest connection with FibroScan results. Thus, in situations where there are limited resources and FibroScan is not accessible, APRI serves as a suitable indicator for predicting significant liver fibrosis.